GLP-1 Dark Horse Files Hong Kong IPO Application with $500 Million Post-Money Valuation

Deep News

Oct 09, 2025

On October 8, 2025, Chengyi Biotechnology's Hong Kong IPO application was accepted. Founded in 2018, the company is a clinical-stage global biotechnology firm that leverages its TRANDD platform to develop next-generation oral small molecule drugs. Its core product, the oral small molecule GLP-1 receptor agonist ECC5004, has the potential to become best-in-class.

Financially, the company recorded revenues of approximately $36.059 million, $221 million, and $557,000 for 2023, 2024, and the first half of 2025, respectively. In late 2023, the company completed a $25 million Series C funding round with a post-money valuation of $498 million.

The company has established a partnership with AstraZeneca, which has already paid $185 million in upfront payments and $60 million in milestone payments. Currently, over 30 domestic companies are developing small molecule GLP-1 products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1104633421"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104633421\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104633421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 14:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104633421","market":"us","top_or_hot":-1,"title":"GLP-1 Dark Horse Files Hong Kong IPO Application with $500 Million Post-Money Valuation","media":"Deep News","content":"<p>On October 8, 2025, Chengyi Biotechnology's Hong Kong IPO application was accepted. Founded in 2018, the company is a clinical-stage global biotechnology firm that leverages its TRANDD platform to develop next-generation oral small molecule drugs. Its core product, the oral small molecule GLP-1 receptor agonist ECC5004, has the potential to become best-in-class.</p>\n<p>Financially, the company recorded revenues of approximately $36.059 million, $221 million, and $557,000 for 2023, 2024, and the first half of 2025, respectively. In late 2023, the company completed a $25 million Series C funding round with a post-money valuation of $498 million.</p>\n<p>The company has established a partnership with AstraZeneca, which has already paid $185 million in upfront payments and $60 million in milestone payments. Currently, over 30 domestic companies are developing small molecule GLP-1 products.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GLP-1 Dark Horse Files Hong Kong IPO Application with $500 Million Post-Money Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGLP-1 Dark Horse Files Hong Kong IPO Application with $500 Million Post-Money Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-10-09 14:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On October 8, 2025, Chengyi Biotechnology's Hong Kong IPO application was accepted. Founded in 2018, the company is a clinical-stage global biotechnology firm that leverages its TRANDD platform to develop next-generation oral small molecule drugs. Its core product, the oral small molecule GLP-1 receptor agonist ECC5004, has the potential to become best-in-class.</p>\n<p>Financially, the company recorded revenues of approximately $36.059 million, $221 million, and $557,000 for 2023, 2024, and the first half of 2025, respectively. In late 2023, the company completed a $25 million Series C funding round with a post-money valuation of $498 million.</p>\n<p>The company has established a partnership with AstraZeneca, which has already paid $185 million in upfront payments and $60 million in milestone payments. Currently, over 30 domestic companies are developing small molecule GLP-1 products.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YANG","symbol_name":"三倍做空富时中国ETF-Direxion","start_time":0,"source_url":"","article_id":"1104633421","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104633421","pubTimestamp":1759992086,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On October 8, 2025, Chengyi Biotechnology's Hong Kong IPO application was accepted. Founded in 2018, the company is a clinical-stage global biotechnology firm that leverages its TRANDD platform to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"YANG":"三倍做空富时中国ETF-Direxion","HSTECH":"恒生科技指数","BK4144":"石油与天然气的储存和运输","HSCEI":"国企指数","07226":"南方两倍做多恒科","GLP":"Global Partners Lp","BK4590":"PTP","BK4614":"Manus概念股"},"translate_title":"GLP-1黑马提交香港IPO申请，投后估值5亿美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YANG":1,"07226":1,"HSTECH":1,"GLP":1,"HSCEI":1},"content_text":"On October 8, 2025, Chengyi Biotechnology's Hong Kong IPO application was accepted. Founded in 2018, the company is a clinical-stage global biotechnology firm that leverages its TRANDD platform to develop next-generation oral small molecule drugs. Its core product, the oral small molecule GLP-1 receptor agonist ECC5004, has the potential to become best-in-class.\nFinancially, the company recorded revenues of approximately $36.059 million, $221 million, and $557,000 for 2023, 2024, and the first half of 2025, respectively. In late 2023, the company completed a $25 million Series C funding round with a post-money valuation of $498 million.\nThe company has established a partnership with AstraZeneca, which has already paid $185 million in upfront payments and $60 million in milestone payments. Currently, over 30 domestic companies are developing small molecule GLP-1 products.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}